Zetia keeps your body from absorbing cholesterol in your diet, and it is generally safe and well-tolerated. So, it’s a good ...

Enrollment Completed on Schedule; Topline Results Expected Mid Q3 2025 ESTERO, FL AND NEW YORK, NY / ACCESS Newswire / June 24, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or ...

Aspire Biopharma enrolls last patient in phase 1 trial of its oral transmucosal fast-acting high-dose aspirin formulation: Estero, Florida Thursday, June 26, 2025, 18:00 Hrs [IST] ...

Press Releases Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation ...

A study to find the right dose of aspirin to reduce the risk of cancer in some patients has found the smallest amount works just as well as larger ones, according to a leading researcher. The ...

Press Releases Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation ...

Press Releases Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation ...

ESTERO, FL AND NEW YORK, NY / ACCESS Newswire / June 24, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending drug delivery ...

Topline results from the study are anticipated by the middle of third quarter of 2025. "The successful completion of patient dosing in our Phase 1 trial is a noteworthy accomplishment.

Press Releases Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation ...

Press Releases Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation ...